The same m6A methylation regulator is expressed differently in different cancers; for example, as an “eraser” in the process of m6A RNA methylation, FTO is highly expressed in breast, liver, and gastric cancer tissues compared to normal tissues, which is associated with poor prognosis, while FTO expression in bladder cancer tissues is lower than that in normal tissues [35,36,37,38]. Here, FTO is linked to urinary bladder carcinoma.